The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH CLL 2020 | Real-world use of ibrutinib in CLL
Loïc Ysebaert, MD, PhD, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulous, France, outlines results of ibrutinib real-world use in patients with chronic lymphocytic leukemia (CLL) and highlights the importance of evaluating real-world data in conjunction with clinical trial results. Dr Ysebaert highlights differences in toxicities associated with real-world ibrutinib use in comparison to clinical trial data, as well as the findings from a French monitoring initiative (AMA), evaluating the importance of clinical nurses alongside clinicians in reducing toxicities associated with ibrutinib as well as improving outcomes in patients with CLL. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
